The UK HIV Drug Resistance Database worked closely with other UK HIV cohort studies to maximise the use of the data. These studies and some examples of joint analyses are listed below:

  • UKCHIC (UK Collaborative HIV Cohort) based at the UCL Research Department of Infection and Population Health
    Virological failure and development of new resistance mutations according to CD4 count at combination antiretroviral therapy initiation. Jose S et al., HIV Med 2015; 17(5) 368-372
  • HARS (HIV and AIDS Reporting System) based at Public Health England
    Recent trends and patterns in HIV-1 transmitted drug resistance in the United Kingdom. Tostevin et al., HIV Med 2017; 18(3) 204-213
  • CHIPS (Collaborative HIV Paediatric Study) based at the MRC Clinical Trials Unit at UCL
    Clinical Status of Adolescents with Perinatal HIV at Transfer to Adult Care in the UK/Ireland. Collins IJ et al., Clin Inf Dis 2017; Epub ahead of print.
  • NSHPC (National Study of HIV in Pregnancy and Children) based at the UCL Institute of Child Health
    Antiretroviral drug resistance in pregnant women living with HIV in England and Wales: Preliminary results from the matching of three national HIV surveillance databases. Byrne L et al., British HIV Association Conference, Brighton April 2015 (oral presentation)
  • UK Register of Seroconverters based at the MRC Clinical Trials Unit at UCL
    Role of HIV infection duration and CD4 cell level at initiation of combination anti-retroviral therapy on risk of failure. Lodi S et al., PLoS One 2013; 8(9): e75608

The UK HIV Drug Resistance Database has also provided data to a number of collaborative studies including:

  1. Study on the Epidemiology of Emerging HIV Drug Resistance in Europe (SEHERE) to describe the temporal trends of HIV drug resistance emerging in treated individuals in Europe. 
  2. The EuroCoord-CHAIN project to compare virological, immunolgical, and clinical outcome up to 12-16 months following initiation of cART, according to markers of virus variability, and relative to the drugs in the regimen. 
  3. The Forum for Collaborative Research for their initiative on Standardisation and Clinical Relevance of HIV Drug Resistance Testing.
  4. The Audit, Information and Analysis Unit on resistance test results on women tested during pregnancy as part of the report on Perinatal Transmission of HIV in England 2002-2005.
  5. To SPREAD, an official European Commission supported programme on ART-naïve patients.
  6. The HIV-CAUSAL Collaboration for work using causal modelling to analyse longitudinal data.
  7. The TenoRes Collaboration for a global assessment of drug resistance after virological failure with first line tenofovir-containing ART